Amyloidosis is considered a rare disease and is not well known. However, there is a belief within the medical community that this disease is not rare, it is underdiagnosed or diagnosed when it is too late to make a difference. The complexity of this disease makes diagnosis one of the biggest challenges affecting patient lives. It is not uncommon to hear from patients that it took multiple years and multiple doctors to ultimately arrive at a correct diagnosis, all the while the disease continued to progress. Until a cure is found, it is imperative to raise awareness within the medical community so that a diagnosis can be determined much sooner, enabling effective treatments and therapies to slow the disease progression and improve patient survival.
What We Are Doing About It
The Amyloidosis Speakers Bureau (ASB) is an initiative focused on educating the medical community about this disease through presentations from amyloidosis patients, an informational video, and our online educational library. Our target audience is the next generation of doctors during their first/second year of medical school, as well as residency programs for physicians launching their medical career.
Medical school curriculums include an introduction to diseases, and may mention amyloidosis in one or two courses, making this the appropriate target audience. Also, at this point medical students have yet to declare their specialty; thus, the ASB can educate future doctors of a wide array of disciplines (e.g., cardiology, gastroenterology, hematology, hepatology, internal medicine, nephrology, neurology, oncology, orthopedics, pathology). This is important because amyloidosis has many variations (e.g., AL, hereditary ATTR, wild-type ATTR) which present themselves in a variety of ways. There are approximately 170 medical schools across the country, each with annual classes of medical students that typically range from 50 to 250. Residency programs are where new doctors are seeing patients and developing their diagnostic skills, which also makes them an important target audience for our initiative (e.g., there are over 580 Internal Medicine programs).
Thus, in aggregate, our goal is to educate thousands of future and new doctors every year. These thousands of doctors will go on to declare their specialties and spread across the country in practice, each seeing hundreds of patients over their career. As a result, the potential to improve and accelerate the diagnosis of amyloidosis from the ASB is immense.
What We Offer
Our offerings are flexible and can accommodate a wide range of situations. We always offer live virtual presentations (e.g., Zoom) and pre-taped patient video presentations, but beginning Fall 2021 we will selectively also offer in-person presentations. Regardless of the format, our patient presentations have been shared with thousands of medical students and physicians across the country, and have been well received.
1a) Live virtual presentation. Hosted by schools and residency programs, our patient speaker provides a live virtual presentation of their journey with this disease, from symptoms through diagnosis and treatment, and life today, followed by real-time Q&A. Typically one hour in length, we are very flexible as to date and time. Upon request, we can also offer presentations with two speakers, showcasing contrasting types of the disease and organ involvement.
1b) Live in-person presentation. As we are transitioning to a post-COVID world, we are open to selective in-person requests, such as those within a curriculum course or presentations to larger audiences. We are happy to discuss individual preferences.
1c) Pre-taped video presentation. If more convenient, we’re happy to share one of our 30-minute pre-taped patient speaker presentations where our speakers take the audience through their early symptoms, diagnosis, treatment, and “new normal” life today, offering their perspective as a patient with a rare disease. This offers the ability to send/post a video link for viewing on ones own time, offering maximum flexibility.
2) Educational video: (a) for medical students: “Amyloidosis Awareness,” narrated by Michael York and developed in conjunction with amyloidosis experts, or (b) for residents: a custom video for residents from one of our medical expert advisors discussing the disease, symptoms, pathway for diagnosis, and summary of treatments today.
3) Access to our continuing education program. For those wanting ongoing information, we offer Powerpoint presentations, videos, podcasts, and live webinars by leading medical professionals about the disease.
For curriculum course directors and residency program directors:
- Our speakers are all volunteers and amyloidosis patients. To prepare them, we provide extensive resources both in story development and presentation skills. Our speakers provide a personal, transparent and candid insight into their journey.
- Our speakers are flexible and can work with preferred dates/times.
- Our offering can be adapted to accommodate individual considerations. For example:
- a live virtual presentation, or
- a live in-person presentation, or
- a pre-taped 30-minute presentation, or
- a custom combination of a speaker’s 30-minute pre-taped presentation and a live abbreviated virtual presentation/Q&A.
- Our offering can be customized to focus on specific types of amyloidosis (e.g., AL, hATTR, ATTRwt) and/or organ involvement (e.g., heart, kidney, liver, GI, nerves) to align with relevant topics.
- Course/program directors can view speaker pre-taped presentations in advance to ensure appropriateness, upon request.
- We do not, nor do our speakers, advocate for industry interests, specific drug treatments, healthcare providers, politics, or religion. As such, we are able to maintain a conflict-free focus.
- There is no cost.
We believe, and feedback confirms, our offering provides a compelling alternative that advances students’ and physicians’ knowledge of amyloidosis while sharing valuable insights from both the patient and clinical perspectives. If interested, please contact us at email@example.com.
We have given over 175 presentations to more than 8,000 medical students & residents.
Our Impact – What Medical Experts Say
In view of the non-specificity of its symptoms, amyloidosis is frequently diagnosed late in the course of the disease. In spite of the fact that therapies are available for virtually all forms of amyloidosis, delays in diagnosis result in end-organ failure which is generally irreversible. There is a major educational gap leading to the late diagnosis of amyloidosis. Thanks to the Amyloidosis Speakers Bureau, providers across the country are being instructed on techniques to suspect and recognize amyloidosis and how to efficiently make the diagnosis in a timely fashion. Incorporating testing for amyloidosis into the work flow of patients with cardiomyopathy, proteinuria, peripheral neuropathy, unexplained weight loss, and smoldering multiple myeloma has been successful. I strongly support incorporation of a member of the Amyloidosis Speakers Bureau into the curriculum of all medical students, all medical residents, and subspecialty fellows in Cardiology, Nephrology, and Neurology.
Comprehensive education remains the best strategy to save lives for this rare disorder and I am strongly supportive and actively participate in the speakers bureau program.
Morie A Gertz, M.D., M.A.C.P., Mayo Clinic
There has been a paradigm shift in the diagnosis and treatment of systemic amyloidosis. Tomorrow’s doctors need to learn about this. I am a hematologist with three decades of clinical experience and research, and deeply involved with amyloidosis, developing a center of excellence at Tufts in the diagnosis and treatment of patients from around the world.
Without question, a major challenge with amyloidosis is its complexity and the subsequent delays in diagnosis. Moreover, there are different types of amyloidosis, including hereditary and non-hereditary. Symptoms vary, as do the organs affected by the amyloid protein. This unpredictable and multi-faceted presentation often delays the diagnosis and therefore the course of treatment. Today we have effective treatments for the common types of systemic amyloidosis, making the delays in diagnosis more tragic in many cases. One of the most important objectives to improve patient survival is earlier diagnosis. With modern tools, this can be accomplished in less than a month. Charolotte Raymond, who developed the original idea of the ASB, has been my patient. Her passion and intensity sparked this initiative, and the partnership forged with Mackenzie’s Mission in early 2019 helped to refine the idea and bring it to fruition. The ASB is well-organized and supported by dozens of expert advisors. The ASB is designed to make a durable impression on medical students – those who will be diagnosing this disease in the not too distant future – because of the quality of their speakers, who are real-life patients, and the up-to-date nature of their extensive educational packet.
I strongly encourage you to integrate the resources made available by the ASB into your first/second-year medical school curriculum. It will make a difference.
Raymond L. Comenzo, M.D., Professor of Medicine, Tufts University School of Medicine
Excellent way to introduce students not only to a rare disease but also to patients’ perspective.
Maria M. Picken, M.D., Ph.D., Director of Surgical Pathology, Loyola University Medical Center
Our Impact – What Medical School Professors Say
By making patient speakers and educational materials curated by ASB’s medical advisors available to medical schools, it is my hope that the Amyloidosis Speaker Bureau will help form durable impressions on medical students and physicians that will translate to more widespread awareness, faster diagnoses, earlier initiation of treatment, and ultimately better survival for amyloid patients. I encourage you to integrate the resources made available by the ASB into your annual curriculum, as it has the potential to significantly alter the course of this disease.
Gordon Huggins, M.D., Associate Professor of Medicine, Tufts University School of Medicine, Cardiologist, Tufts Medical Center
The ASB was such a wonderful organization to work with – they were willing to provide different options to make the experience meaningful for our students. The speaker was truly outstanding. The students had many questions and she answered them thoughtfully and graciously. We will definitely do this again for our students and are grateful to the ASB for this service.
Deborah E. Powell, M.D., Dean Emerita and Professor of Laboratory Medicine and Pathology, University of Minnesota Medical School
The opportunity for second year medical students to hear the story of a patient with amyloid is invaluable. The presentation addressed aspects of pathophysiology they are learning and the human side of medicine. This presentation format offered an excellent teaching opportunity to inform doctors-in-training about this serious disease. Our students gained insight into the patient’s journey through diagnosis, treatment and the challenges ahead. We all appreciated the patient’s generosity in sharing her experiences. Having patients teaching medical students about amyloidosis will have a lasting impact on our future doctors with increasing awareness of this disease and ultimately will help future patients.
Theresa Kristopaitis, M.D., Professor, Assistant Dean for Curriculum Integration, Loyola University Stritch School of Medicine
This organization is very well-run and professional. The speakers were engaging, well-informed and also delivered some great first-hand advice to students on how to approach patients. They were quite encouraging and the format of the panel made for a very efficient session.
Kimberly Densmore, Medical Colloquia Coordinator, University of Illinois College of Medicine
The students really appreciated hearing about the disease from the patient’s perspective. It was a very moving and thought-provoking experience. It is one thing to read about a disease. It becomes an unforgettable experience to hear an actual patient describe their clinical story.
Carol A Waksmonski, M.D., Cardiologist and course director for the Cardiovascular Section of “The Body – in Health and in Disease”, a first year course for all Columbia medical and dental students. New York-Presbyterian / Columbia University Irving Medical Center / Vagelos College of Physicians and Surgeons (Columbia Medical School)
Our Impact – What Residency Programs Say
Great speaker, very engaging and really great to hear a real life experience from the patient’s perspective. As a physician, I was able to get a lot of insight and pointers from him.
Laredo Medical Center / TIGMER internal medicine program
This presentation is an eye opener of the unspecificity of symptoms related to amyloidosis and how I as a provider can easily miss the diagnosis if there is little or no suspicion. Obtaining these through history from the patients, including family history, is also essential.
Meharry Medical College / Nashville General Hospital
This was an excellent presentation and I would highly recommend to other residency programs!
Western Michigan University Homer Stryker M.D. School of Medicine
Our Impact – What Medical Students Say
Our school’s curriculum is organized by different organ systems, so I often think that multi-system diseases, such as amyloidosis, aren’t presented as clearly as other diseases only affecting one organ system. I learned so much about the complexity and severity of amyloidosis because of this presentation and I think hearing Beth’s story really helped me to understand why this disease often goes undiagnosed. Hearing her journey will remind me to advocate for my future patients with amyloidosis and other complex, incurable diseases. Sydney Shade, MD Candidate, Geisinger Commonwealth School of Medicine
The presentation helped put a human face to a disease that is often only seen in test questions. You can easily forget a question, but it is much harder to forget a face. Mayo Clinic Alix School of Medicine; Ramin Garmany, MD-PhD candidate
Amyloidosis is something we often call a “Zebra” disease. Its presentation is odd and confusing and its treatments few. Since AL is most treatable early, keeping it in your differential is so important. Having ASB talk at my school reinforced that idea. I believe that I will be a better physician for having attend this lecture. University of Illinois College of Medicine Rockford; Rachel Miller, MD Candidate
This presentation was a wonderful supplement to my medical education because it brought amyloidosis to life and reminded me that there are actual people behind these devastating diseases. During the second year of medical school, it can seem very disconnected and abstract to study disease after disease and memorize the clinical presentations, treatments, and prognoses. It is refreshing to hear from an actual patient and be reminded of why we’re in medical school. Loyola University Stritch School of Medicine, Alexis Stefaniak, MD Candidate
Being able to hear from a patient with a specific disease, whether common, rare, or somewhere in between, is so important for both our academic education as well as our development as doctors. During the preclinical years, it can be easy to get lost in the textbook descriptions of patients and forget about what real patients actually go through. Talking to real patients makes me remember why I went into medicine in the first place. Yale School of Medicine, Alexander Hirsch, MD Candidate
As a medical student, I have spoken to several patients and have participated in many patient presentations, but they always seem to miss the mark. We need to hear about the emotional aspects and challenges at home that accompany the journey to diagnosis and treatment. This presentation covered all of that with the clinical information included. Raymond Stemrich, MD Candidate, Geisinger Commonwealth School of Medicine
As medical students we often only get the textbook definition of so many diseases, and when we read over the symptoms and treatments we merely just memorize and pass them over. Mackenzie’s Mission brings so much more than just the textbook definition of Amyloidosis. It brings the emotion, the struggle, pain, frustration, things that we don’t see on paper. This is so important for us as future physicians to see and hear, because this disease is not just a question on the test it is somebody’s life. And, it truly reminded me of why I am here. More medical students need to hear this! Zachary Hostoffer, DO Candidate, Lake Erie College of Osteopathic Medicine
The speaker’s ability to put a face and experience behind a disease is so much stronger than a textbook will ever be. I will now be much more likely to appropriately add amyloidosis to a differential diagnosis moving forward in my clinical rotations and career. William Bradford, MD Candidate, Tufts University School of Medicine
I would highly recommend medical schools to allow a speaker from the Amyloidosis Speakers Bureau to give a talk on his/her medical journey. Our speaker was incredibly powerful, and shed light on an important disease that unfortunately has been improperly diagnosed for years. By allowing a speaker to provide his/her personal story, medical students will be much more informed about this surprisingly prevalent disease, which will help guide their clinical decisions as attending physicians. Matthew Trendowski, MD Candidate, Wayne State University School of Medicine
Mission: “Patients Teaching Students”
The mission of the Amyloidosis Speakers Bureau is to educate the medical community about amyloidosis through patient stories which, we believe, will contribute to earlier diagnoses of the disease and lead to improved patient survival.
Our vision is a world where amyloidosis is a widely recognized disease, identification methods are established and integrated into mainstream protocols, and diagnosis happens early in the onset of the disease. In this world, there will be no need for a speakers bureau.
We are proud to have these medical experts and influencers in the world of amyloidosis, some of whom are also patients, as advisors to support our initiative. Our advisors are active in our efforts and contribute their specialized expertise in a variety of ways, such as educational development, medical school introductions, and patient speaker assessment/development. We are extremely grateful for their assistance and believe that, thanks to their contribution, the ASB will make an even bigger difference in the diagnoses of this disease.
Janice F. Wiesman, M.D., FAAN – In Memoriam
In the summer of 2017, Charolotte Raymond was undergoing treatment for amyloidosis at Tufts Medical Center. There, she met with Gordon S. Huggins, M.D., Cardiologist and Associate Professor at Tufts University School of Medicine. After learning more about Charolotte’s story, Dr. Huggins invited her to speak to his second-year medical students. He explained that medical school’s second-year curriculum focuses on illnesses and diseases, and hearing about a rare disease directly from a patient would have a lasting impact on the audience of future doctors. In fact, the feedback from Charolotte’s presentation was so meaningful that it inspired her to develop the concept of a speakers bureau, comprised of patients, whose focus was to reach out to the medical schools across the country and raise awareness of the disease. After much searching, Charolotte approached Mackenzie’s Mission, whose purpose was strongly oriented towards raising awareness, about bringing her concept to fruition. In February 2019 the Amyloidosis Speakers Bureau was launched.
Neither Mackenzie’s Mission nor the Amyloidosis Speakers Bureau endorse any company, product or treatment. Patient speakers are unpaid volunteers who may, at their own discretion, mention specific treatments, healthcare centers, and physicians while sharing their personal journey.
The Amyloidosis Speakers Bureau is supported predominantly by Mackenzie’s Mission through all facets of program management, fundraising activities and general donations, and to a lesser part by directed donations and grants from Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Eidos Therapeutics, Ionis Pharmaceuticals, Pfizer Inc, and Prothena Bioscience Ltd. No donor or grantor has any influence over any facet of the ASB operations.